Pharma Hiring in Q3: Why a €20K Raise Alone No Longer Closes the Deal

Automation, QA, and CQV are the three roles defining the pharma hiring market this quarter, and the shortage in automation specifically has moved beyond tight into structural: there are simply more open roles than candidates to fill them. That imbalance is now shaping not just who gets hired, but how offers have to be built to land them at all.

Automation's Shortage Reflects Where Pharma Manufacturing Is Headed

QA, automation, and CQV (commissioning, qualification and validation) are the three hardest roles to fill this quarter, with automation carrying the most acute imbalance between open roles and available candidates. This isn't a speculative hiring spike — it reflects pharma manufacturing's ongoing scaling and integration of automated processes into production and quality systems, a shift that has been building for several years and shows no sign of plateauing. CQV demand follows a similar logic: as more automated and upgraded processes come online, each one requires validation before it can run, keeping demand for CQV specialists tied directly to the pace of that broader automation build-out.

The hot-and-cold split adds a useful nuance for hiring managers. While QA is one of the hardest roles to fill, quality control — an adjacent but distinct discipline — is comparatively well supplied, alongside technical writing. Employers assuming that scarcity in one quality-adjacent function implies scarcity across the board risk misjudging both their search difficulty and their budget for roles that actually have a healthier candidate pool.

Flat Base Pay Is Colliding With Aggressive Counteroffers

Starting salaries in pharma have not moved much since last year. But that stability at the point of hire is misleading, because the real compensation pressure is showing up elsewhere: counteroffers have become significant and frequent, driven directly by the skills shortage rather than general pay inflation. For hiring managers, this means the greater risk isn't necessarily losing a competitive external search — it's losing a candidate at the finish line once their current employer realises what's at stake and moves to retain them.

The contractor market makes the scarcity even more visible. Day rates continue to climb, and notably, that increase isn't confined to senior, highly experienced contractors — rates for less experienced candidates are rising too. That's a meaningful signal: when pricing pressure starts compressing the usual gap between junior and senior contract rates, it typically means the shortage has become severe enough that employers are competing for capacity at every experience level, not just at the top of the market.

Candidates Are Buying a Five-Year Story, Not Just a Salary

Progression has become the dominant factor in candidate decision-making. Candidates are asking directly where they'll stand in five years — both in terms of role and salary — and offers that can't answer that question credibly are struggling to compete, regardless of the base pay attached to them.

This quarter produced a clear demonstration of what actually wins in this market: a client secured a candidate not by raising the offer alone, but by pairing a €20,000 increase with an explicit two-year progression path that named the specific salary the candidate could expect to be earning by the end of it. The raise created interest; the specificity of the future earnings closed the deal. For hiring managers competing for QA, automation, or CQV talent, this suggests that a well-structured, clearly costed progression plan may now be doing as much work as the headline offer itself — and that vague promises of "growth opportunities" are unlikely to hold up against a competitor willing to put numbers on the table.

In pharma's current market, the offer that wins isn't necessarily the highest one — it's the one candidates can see the end of. Get in touch with our team for custom benchmarking and on structuring progression paths that actually close.